Insulin Copay Bill Advances In What Could Be US Senate Democrats Last Gasp For Price Reform
Executive Summary
Though popular, the proposal to cap insulin copays is a relatively minor part of the drug pricing reform package included in the stalled Build Back Better Act. But it may represent Democrats’ best chance of passing any drug pricing-related legislation while they still hold majorities in Congress.
You may also be interested in...
Rx Pricing: Insulin Costs Would Go Up Under Senate Bill; Biden Pushes Summer Action On Broader Plan
CBO highlights the pharma-friendly nature of Senate’s plan to limit patient cost-sharing for insulin. Meanwhile, White House urges Senate to pass Democrat’s more comprehensive and pharma-negative drug pricing bill instead of waiting for the revival of the Build Back Better deal.
Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.
PBM Formulary Exclusions On The Rise, PhRMA Says
According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval.